Selected research
Industry Growth & Trends
Global Life Science CDMO Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Life Science CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Life Science CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Life Science CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Life Science CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Life Science CDMO market include Lonza Group, Thermo Fisher Scientific, Catalent, WuXi Biologics, Samsung Biologics, Siegfried, Fujifilm Diosynth Biotechnologies, Lars Petersen and Recipharm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Life Science CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Life Science CDMO market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Life Science CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Life Science CDMO.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Life Science CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Life Science CDMO Market by Company
Lonza Group
Thermo Fisher Scientific
Catalent
WuXi Biologics
Samsung Biologics
Siegfried
Fujifilm Diosynth Biotechnologies
Lars Petersen
Recipharm
Boehringer Ingelheim
MilliporeSigma
Aenova Group
AGC Parma Chemicals
GenScript
Novartis
Sai Life Sciences
Life Science CDMO Segment by Type
Active Pharmaceutical Ingredient (API) CDMO
Biologics CDMO
Finished Dosage Form (FDF) CDMO
Others
Life Science CDMO Segment by Application
Pharmaceutical
Clinical
Research
Life Science CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Life Science CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Life Science CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Life Science CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Life Science CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Active Pharmaceutical Ingredient (API) CDMO
- Biologics CDMO
- Finished Dosage Form (FDF) CDMO
- Others
Applications
- Pharmaceutical
- Clinical
- Research
Companies covered
- Lonza Group
- Thermo Fisher Scientific
- Catalent
- WuXi Biologics
- Samsung Biologics
- Siegfried
- Fujifilm Diosynth Biotechnologies
- Lars Petersen
- Recipharm
- Boehringer Ingelheim
- MilliporeSigma
- Aenova Group
- AGC Parma Chemicals
- GenScript
- Novartis
- Sai Life Sciences
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Life Science CDMO Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Life Science CDMO Market Size by Region (2021-2032)
- 1.4.1 Global Life Science CDMO Market Size by Region (2021-2026)
- 1.4.2 Global Life Science CDMO Market Size by Region (2027-2032)
- 1.5 Key Regions Life Science CDMO Market Size (2021-2032)
- 1.5.1 North America Life Science CDMO Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Life Science CDMO Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Life Science CDMO Market Size Growth Rate (2021-2032)
- 1.5.4 South America Life Science CDMO Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Life Science CDMO Market Size Growth Rate (2021-2032)
2 Life Science CDMO Market by Type
- 2.1 Type Introduction
- 2.1.1 Active Pharmaceutical Ingredient (API) CDMO
- 2.1.2 Biologics CDMO
- 2.1.3 Finished Dosage Form (FDF) CDMO
- 2.1.4 Others
- 2.2 Global Life Science CDMO Market Size by Type
- 2.2.1 Global Life Science CDMO Market Size Overview by Type (2021-2032)
- 2.2.2 Global Life Science CDMO Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Life Science CDMO Market Size Forecasted by Type (2027-2032)
- 2.3 Global Life Science CDMO Market Size by Regions
- 2.3.1 North America Life Science CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Life Science CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Life Science CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Life Science CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Life Science CDMO Market Size Breakdown by Type (2021-2026)
3 Life Science CDMO Market by Application
- 3.1 Type Introduction
- 3.1.1 Pharmaceutical
- 3.1.2 Clinical
- 3.1.3 Research
- 3.2 Global Life Science CDMO Market Size by Application
- 3.2.1 Global Life Science CDMO Market Size Overview by Application (2021-2032)
- 3.2.2 Global Life Science CDMO Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Life Science CDMO Market Size Forecasted by Application (2027-2032)
- 3.3 Global Life Science CDMO Market Size by Regions
- 3.3.1 North America Life Science CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Life Science CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Life Science CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Life Science CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Life Science CDMO Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Life Science CDMO Industry Trends
- 4.2 Life Science CDMO Industry Drivers
- 4.3 Life Science CDMO Industry Opportunities and Challenges
- 4.4 Life Science CDMO Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Life Science CDMO Revenue (2021-2026)
- 5.2 Global Life Science CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Life Science CDMO Key Company Headquarters & Area Served
- 5.4 Global Life Science CDMO Company, Product Type & Application
- 5.5 Global Life Science CDMO Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Life Science CDMO Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Life Science CDMO Players Market Share by Revenue in 2025
- 5.6.3 2025 Life Science CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Lonza Group
- 6.1.1 Lonza Group Company Information
- 6.1.2 Lonza Group Business Overview
- 6.1.3 Lonza Group Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Lonza Group Life Science CDMO Product Portfolio
- 6.1.5 Lonza Group Recent Developments
- 6.2 Thermo Fisher Scientific
- 6.2.1 Thermo Fisher Scientific Company Information
- 6.2.2 Thermo Fisher Scientific Business Overview
- 6.2.3 Thermo Fisher Scientific Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Thermo Fisher Scientific Life Science CDMO Product Portfolio
- 6.2.5 Thermo Fisher Scientific Recent Developments
- 6.3 Catalent
- 6.3.1 Catalent Company Information
- 6.3.2 Catalent Business Overview
- 6.3.3 Catalent Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Catalent Life Science CDMO Product Portfolio
- 6.3.5 Catalent Recent Developments
- 6.4 WuXi Biologics
- 6.4.1 WuXi Biologics Company Information
- 6.4.2 WuXi Biologics Business Overview
- 6.4.3 WuXi Biologics Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 WuXi Biologics Life Science CDMO Product Portfolio
- 6.4.5 WuXi Biologics Recent Developments
- 6.5 Samsung Biologics
- 6.5.1 Samsung Biologics Company Information
- 6.5.2 Samsung Biologics Business Overview
- 6.5.3 Samsung Biologics Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Samsung Biologics Life Science CDMO Product Portfolio
- 6.5.5 Samsung Biologics Recent Developments
- 6.6 Siegfried
- 6.6.1 Siegfried Company Information
- 6.6.2 Siegfried Business Overview
- 6.6.3 Siegfried Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Siegfried Life Science CDMO Product Portfolio
- 6.6.5 Siegfried Recent Developments
- 6.7 Fujifilm Diosynth Biotechnologies
- 6.7.1 Fujifilm Diosynth Biotechnologies Company Information
- 6.7.2 Fujifilm Diosynth Biotechnologies Business Overview
- 6.7.3 Fujifilm Diosynth Biotechnologies Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Fujifilm Diosynth Biotechnologies Life Science CDMO Product Portfolio
- 6.7.5 Fujifilm Diosynth Biotechnologies Recent Developments
- 6.8 Lars Petersen
- 6.8.1 Lars Petersen Company Information
- 6.8.2 Lars Petersen Business Overview
- 6.8.3 Lars Petersen Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Lars Petersen Life Science CDMO Product Portfolio
- 6.8.5 Lars Petersen Recent Developments
- 6.9 Recipharm
- 6.9.1 Recipharm Company Information
- 6.9.2 Recipharm Business Overview
- 6.9.3 Recipharm Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Recipharm Life Science CDMO Product Portfolio
- 6.9.5 Recipharm Recent Developments
- 6.10 Boehringer Ingelheim
- 6.10.1 Boehringer Ingelheim Company Information
- 6.10.2 Boehringer Ingelheim Business Overview
- 6.10.3 Boehringer Ingelheim Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Boehringer Ingelheim Life Science CDMO Product Portfolio
- 6.10.5 Boehringer Ingelheim Recent Developments
- 6.11 MilliporeSigma
- 6.11.1 MilliporeSigma Company Information
- 6.11.2 MilliporeSigma Business Overview
- 6.11.3 MilliporeSigma Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 MilliporeSigma Life Science CDMO Product Portfolio
- 6.11.5 MilliporeSigma Recent Developments
- 6.12 Aenova Group
- 6.12.1 Aenova Group Company Information
- 6.12.2 Aenova Group Business Overview
- 6.12.3 Aenova Group Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Aenova Group Life Science CDMO Product Portfolio
- 6.12.5 Aenova Group Recent Developments
- 6.13 AGC Parma Chemicals
- 6.13.1 AGC Parma Chemicals Company Information
- 6.13.2 AGC Parma Chemicals Business Overview
- 6.13.3 AGC Parma Chemicals Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 AGC Parma Chemicals Life Science CDMO Product Portfolio
- 6.13.5 AGC Parma Chemicals Recent Developments
- 6.14 GenScript
- 6.14.1 GenScript Company Information
- 6.14.2 GenScript Business Overview
- 6.14.3 GenScript Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 GenScript Life Science CDMO Product Portfolio
- 6.14.5 GenScript Recent Developments
- 6.15 Novartis
- 6.15.1 Novartis Company Information
- 6.15.2 Novartis Business Overview
- 6.15.3 Novartis Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Novartis Life Science CDMO Product Portfolio
- 6.15.5 Novartis Recent Developments
- 6.16 Sai Life Sciences
- 6.16.1 Sai Life Sciences Company Information
- 6.16.2 Sai Life Sciences Business Overview
- 6.16.3 Sai Life Sciences Life Science CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Sai Life Sciences Life Science CDMO Product Portfolio
- 6.16.5 Sai Life Sciences Recent Developments
7 North America
- 7.1 North America Life Science CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Life Science CDMO Market Size by Country (2021-2026)
- 7.3 North America Life Science CDMO Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Life Science CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Life Science CDMO Market Size by Country (2021-2026)
- 8.3 Europe Life Science CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Life Science CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Life Science CDMO Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Life Science CDMO Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Life Science CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Life Science CDMO Market Size by Country (2021-2026)
- 10.3 South America Life Science CDMO Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Life Science CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Life Science CDMO Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Life Science CDMO Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst